Semaglutide voor de preventie van diabetes na transplantatie mellitus (SPOT-DM)
The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
A kidney transplant is the best treatment for people living with kidney failure as it allows people to live longer with a better quality of life. However, one in four kidney transplant recipients will develop diabetes after transplant. This is largely due to the medications that must be used to prevent rejection of the transplant. Kidney transplant recipients who get diabetes after transplant are up to three times more likely to have heart disease and die prematurely. To date, there are no treatments to prevent the development of diabetes after kidney transplant. Semaglutide is a drug that is commonly used to treat diabetes and obesity. The investigators believe that semaglutide is a safe and effective drug which can prevent the development of diabetes in kidney transplant recipients. Therefore, the investigators are conducting a study where kidney transplant recipients who are at increased risk of developing diabetes after transplant will receive semaglutide for 24 weeks after their transplant. The study will determine whether semaglutide is effective in decreasing blood sugar levels and the rate of diabetes. The investigators will also study other important markers of health including body weight and cholesterol levels as well as liver, kidney and heart function. Diabetes after transplant is a common problem, and preventing it is extremely important to allowing kidney transplant recipients to live longer and better lives. The results of this study will allow the investigators to determine if semaglutide is a safe and effective option for the prevention of diabetes in kidney transplant recipients.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Cheng Xu
- Telefoonnummer: 8508 416-340-4800
- E-mail: cheng.xu@uhn.ca
Studie Locaties
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- St. Paul's Hospital
-
Contact:
- Vikas S Srinivasan, MD PhD FRCPC
- Telefoonnummer: 604-806-8970
- E-mail: vikas.sridhar@phc.ca
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2N2
- Toronto General Hospital
-
Contact:
- Cheng Xu
- Telefoonnummer: 8508 416-340-4800
- E-mail: cheng.xu@uhn.ca
-
Hoofdonderzoeker:
- Sunita Singh, MD MSc FRCPC
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Signed and dated written informed consent.
-
Adult (≥18 years) recipients of a living or deceased donor kidney transplant
-
Between 4- and 12-weeks post kidney transplant
-
Stable kidney function defined as an eGFR > 30 ml/min/1.73m2 (CKD-EPI)
-
At risk for PTDM at the time of transplant based on the following criteria:
- BMI ≥ 25 kg/m2, or
- Fasting plasma glucose 6.1-6.9 mmol/L (impaired fasting glucose), or
- 2hr OGTT plasma glucose 7.8-11.0 (impaired glucose tolerance), or
- HbA1C 5.5-6.4% (at risk for DM or prediabetes).
Exclusion Criteria:
- Established diagnosis of type 1 or type 2 DM as per Diabetes Canada (including the need for glucose-lowering therapy for hyperglycemia at the time of screening)
- Kidney-Pancreas transplant recipient
- Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening
- History of pancreatitis
- Personal or family history of medullary thyroid cancer or MEN2B
- Women who are pregnant, nursing or plan on becoming pregnant whilst in the trial
- Use of GLP1RA in the 30 days prior to screening
- Contraindication to MRI (applicable only to those undergoing the optional MRI assessments)
- With known or suspected hypersensitivity to semaglutide or related products
- Patient not able to understand and comply with study requirements, based on Investigator's judgment.
- Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcom
- History of glucose-galactose malabsorption syndrome
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Semaglutide
Patients will be up-titrated as tolerated starting at 0.25 mg subcutaneous semaglutide once weekly for 4 weeks, followed by 0.5 mg, 1.0 mg, and 1.7 mg semaglutide for 4 weeks each, and then 2.4 mg subcutaneous semaglutide once weekly for 8 weeks. Semaglutide can be down-titrated by the investigator to lower doses or up-titrated at slower rates if not tolerated by the participant. |
Subcutaneous semaglutide 0.25mg for 4 weeks. Subcutaneous semaglutide 0.5mg for 4 weeks. Subcutaneous semaglutide 1.0 mg for 4 weeks. Subcutaneous semaglutide 1.7 mg for 4 weeks Subcutaneous semaglutide 2.4 mg for 8 weeks |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
2-hour OGTT
Tijdsspanne: 24 weeks
|
The primary outcome of this study is the change in plasma glucose at 120 minutes following a 75g oral glucose challenge (2-hour OGTT) at 24 weeks. The 2-hour OGTT was selected as the primarily outcome in this study for the following reasons: 1) In selecting a surrogate outcome for PTDM in KTR, there are limitations to HbA1c and fasting glucose in this population; 2) The 2-hour OGTT is the recommended test for the diagnosis of PTDM in KTR and 3) The use of OGTT has been used in other PTDM prevention studies. |
24 weeks
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Systolische bloeddruk
Tijdsspanne: 24 weken
|
24 weken
|
|
|
Verandering in lichaamsgewicht
Tijdsspanne: 24 weken
|
24 weken
|
|
|
Verandering in tailleomtrek
Tijdsspanne: 24 weken
|
24 weken
|
|
|
Verandering in HbA1c
Tijdsspanne: 24 weken
|
24 weken
|
|
|
Verandering in nuchtere bloedglucose
Tijdsspanne: 24 weken
|
24 weken
|
|
|
Verandering in seruminsuline
Tijdsspanne: 24 weken
|
24 weken
|
|
|
Verander in het nuchtere lipideprofiel
Tijdsspanne: 24 weken
|
24 weken
|
|
|
Diastolische bloeddruk
Tijdsspanne: 24 weken
|
24 weken
|
|
|
Gemiddelde arteriële druk
Tijdsspanne: 24 weken
|
24 weken
|
|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Tijdsspanne: 24 weeks
|
: The side effects of GLP-1RA have been well described and will be assessed at each study visit. Adverse events include AKI, hypoglycemia, volume depletion, GI intolerance, amputations, pancreatitis, hepatobiliary complications and injection site or allergic reactions, infectious complications (any source), and malignancy. Episodes of biopsy-proven acute rejection (as defined by the Banff criteria), death-censored graft failure (defined as the need for initiation of chronic dialysis or re-transplantation) or death with graft function (defined as death with a functioning allograft) will also be collected. Kidney transplantation assures complete denervation of the transplanted kidney and the renal vasoconstrictive response in the setting of intravascular volume depletion is diminished in KTR. Therefore, frequent monitoring for adverse events has been integrated in our study design, occurring on 10 separate occasions, to capture these adverse events should they occur. |
24 weeks
|
|
Estimated GFR
Tijdsspanne: 24 weeks
|
Calculated by CKD-EPI 2021 equation |
24 weeks
|
|
GFR
Tijdsspanne: 24 weeks
|
Measured using 24-urine collection for creatinine, standardized per 1.73m2 body surface area. And estimated using CKD-EPI 2021 equation. |
24 weeks
|
|
Albuminuria
Tijdsspanne: 24 weeks
|
measuring urine albumin excretion from a 24-hour urine collection |
24 weeks
|
|
Natriuresis
Tijdsspanne: 24 weeks
|
Assessed with a 24-hour urine collection for sodium excretion |
24 weeks
|
|
Percentage of body fat
Tijdsspanne: 24 weeks
|
Bioimpedance analysis |
24 weeks
|
|
Change in liver enzymes
Tijdsspanne: 24 weeks
|
ALT and AST |
24 weeks
|
|
Change in fibrosis level
Tijdsspanne: 24 weeks
|
Transient elastography |
24 weeks
|
|
Change in steatosis level
Tijdsspanne: 24 weeks
|
Transient elastography |
24 weeks
|
|
Percentage of extracellular fluid
Tijdsspanne: 24 weeks
|
Bioimpedance analysis |
24 weeks
|
Andere uitkomstmaten
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in kidney oxygenation (R2*)
Tijdsspanne: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney fibrosis (ADC)
Tijdsspanne: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney perfusion
Tijdsspanne: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney volume
Tijdsspanne: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney inflammation (T1)
Tijdsspanne: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Sunita Singh, MD MSc FRCPC, University Health Network, Toronto General Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- 25-5093
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .